Early Detection Research Network


CCL18 has been described in the literature as a potential biomarker for ovarian, bladder, breast, and colorectal cancer. CCL18 has not been identified previously in serum as a lung cancer biomarker, but it was observed up-regulated in lung cancer in the aptamer proteomic technology study (Ostroff et al, 2010).
CCL18, also known as MIP-4, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.
Lung Reference Set C Application: Rachel Ostroff - SomaLogics (2010)

Analysis of the EDRN lung biomarker samples will enable the next step in development of a clinical diagnostic assay for the differential diagnosis of lung cancer or benign disease in patients with indeterminant pulmonary nodules. The objective is to develop a blood test with sufficient accuracy to identify lung cancer in these patients, which will aid the treating physician in decisions to recommend invasive procedures or watchful waiting.